KDOQI (Kidney Disease Outcomes Quality Initiative)

NKF KDOQI GUIDELINES

Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | History of KDOQI

 

KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease


Acronyms and Abbreviations

4-D Die Deutsche Diabetes Dialyse Studie

4S Scandinavian Simvastatin Survival Study

ACCORD Action to Control Cardiovascular Risk in Diabetes

ACVD Atherosclerotic Cardiovascular Disease

AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study

AHA American Heart Association

AJKD American Journal of Kidney Diseases

ALERT Assessment of Lescol in Renal Transplantation

ALLHAT Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial

ALLIANCE Aggressive Lipid Lowering Initiation Abates New Cardiac Events

ASPEN Atorvastatin as Prevention of Coronary Heart Disease Endpoints in Patients with Non-Insulin-Dependent Diabetes Mellitus

AST American Society of Transplantation

ATP III Adult Treatment Panel III

AUC Area under the (concentration-time) curve

AZA Azathioprine

BIP Bezafibrate Infarction Prevention

CARDS Collaborative Atorvastatin Diabetes Study

CARE Cholesterol and Recurrent Events

CHD Coronary Heart Disease

CHOL Cholesterol

CK Creatinine phosphokinase

CKD Chronic kidney disease

CMV Cytomegalovirus

Cr Creatinine (serum)

CsA CyclosporineA

CVD Cardiovascular disease

DOQI Dialysis Outcomes Quality Initiative

EDTA European Dialysis and Transplantation Association

EPA Eicosapentaenoic acid (20:n-3)

ESRD End-stage renal disease

EXCEL Expanded Clinical Evaluation of Lovastatin

FIELD Fenofibrate Intervention and Event Lowering in Diabetes

FMC Fresenius Medical Care

GFR Glomerular filtration rate

HD Heart disease

HDL High-density lipoprotein

HPS The Heart Protection Study

IDEAL Incremental Decrease in Endpoints Through Aggressive Lipid Lowering

IDL Intermediate-density lipoproteins

KDOQI Kidney Disease Outcomes Quality Initiative

LDL Low-density lipoprotein

LIPID Long-Term Intervention with Pravastatin in Ischaemic Disease

LMWH Low molecular weight heparin

Lp(a) Lipoprotein (a)

MI Myocardial infarction

MIRACL Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering

MMF Mycophenolate mofetil

MRC Medical Research Council

N Number (of data points)

NCEP National Cholesterol Education Program

NCEP-C National Cholesterol Education Program-Children

NHANES National Health and Nutrition Examination Survey

NHLBI National Heart, Lung and Blood Institute

NIH National Institutes of Health

NKF National Kidney Foundation

NKF-KDOQI National Kidney Foundation Kidney Disease Outcomes Quality Initiative

NS Nephrotic syndrome

PDAY Pathobiological Determinants of Atherosclerosis in Youth

PREVEND IT Prevention of REnal and Vascular ENdstage Disease Intervention Trial

PRINCE Pravastatin Inflammation/C-Reactive Protein Evaluation

PROSPER Prospective Study of Pravastatin in the Elderly at Risk

PROVE IT Pravastatin or Atorvastatin in Evaluation and Infection Therapy

SEARCH Study Evaluating Additional Reductions in Cholesterol and Homocysteine

SHARP The Study of Heart and Renal Protection

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels

TG, TRIG Triglycerides

TLC Therapeutic lifestyle changes

TNT Treating to New Targets

USFDA United States Food and Drug Administration

VA-HIT Veterans Administration High-Density Lipoprotein Cholesterol Intervention Trial

VLDL Very low-density lipoprotein

WOSCOPS West of Scotland Coronary Prevention Study


2003 National Kidney Foundation, Inc.